Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SB 1758Sesión 2026

Qué cambió entre versiones

1137 párrafos cambiaron+1094 palabras agregadas−980 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

Florida Senate

-

2026

CS for CS for SB 1758

By

the CommitteeCommittees on Appropriations; and Health Policy; and Senators Gaetz and

Brodeur

Senators Gaetz, Brodeur, and Massullo

588-02430-26576-03342-26 20261758c120261758c2

1 A bill to be entitled

90 párrafos sin cambios

2 An act relating to public assistance; amending s.

3 409.904, F.S.; authorizing the Agency for Health Care

4 Administration to conduct retrospective reviews and

5 audits of certain claims under the state Medicaid

6 program for a specified purpose; creating s. 409.9041,

7 F.S.; providing legislative findings; requiring the

8 agency to seek federal approval to implement mandatory

9 work and community engagement requirements for able

10 bodied adults as a condition of obtaining and

11 maintaining Medicaid coverage; prohibiting the agency

12 from implementing such requirements until certain

13 conditions are met; requiring the agency, in

14 consultation with the Department of Children and

15 Families, to develop a business plan to implement

16 specified provisions; specifying requirements for the

17 plan; requiring the agency to submit the plan to the

18 Governor and the Legislature by a specified date;

19 specifying populations that are subject to such work

20 and community engagement requirements; providing

21 exceptions; defining the term “family caregiver”;

22 specifying the types of activities which may satisfy

23 the work and community engagement requirements;

24 providing that a certain population is required to

25 engage in work or community engagement activities only

26 during standard school hours; requiring persons

27 eligible for Medicaid to demonstrate compliance with

28 the work and community engagement requirements at

29 specified times as a condition of maintaining Medicaid

30 coverage; requiring the agency to develop a process

31 for ensuring compliance with the work and community

32 engagement requirements; requiring that such process

33 align, to the extent possible, with certain existing

34 processes; requiring the department to verify

35 compliance with the work and community engagement

36 requirements at specified intervals; requiring the

37 agency, in coordination with the department, to

38 conduct outreach regarding implementation of the work

39 and community engagement requirements; specifying

40 requirements for such outreach; specifying procedures

41 in the event of noncompliance; requiring the agency,

42 in coordination with the department, to notify a

43 Medicaid recipient of a finding of noncompliance and

44 the impact to eligibility for continued receipt of

45 services; specifying requirements for such notice;

46 amending s. 409.905, F.S.; deleting a requirement that

47 the agency discontinue its hospital retrospective

48 review program under certain circumstances; revising

49 construction; requiring the agency to maintain cost

50 effective purchasing practices in its coverage of

51 hospital inpatient services rendered to Medicaid

52 recipients; amending s. 409.906, F.S.; requiring the

53 agency to seek federal approval to implement a program

54 for expanded coverage of home- and community-based

55 behavioral health services for a specified population;

56 specifying the goal of the program; requiring the

57 agency to work in coordination with the department to

58 develop the program; requiring the agency and the

59 department to develop certain estimates and submit

60 them to the Legislature in a specified manner before

61 the program may be implemented; amending s. 409.91195,

62 F.S.; revising the purpose of the Medicaid

63 Pharmaceutical and Therapeutics Committee to include

64 creation of a Medicaid preferred physician

65 administered drug list, a Medicaid preferred product

66 list, and a high-cost drug list; requiring the agency

67 to adopt such lists upon recommendation of the

68 committee; specifying the frequency with which the

69 committee must review such lists for any recommended

70 additions or deletions; specifying parameters for such

71 recommended additions and deletions; providing that

72 reimbursement for drugs not included on such lists is

73 subject to prior authorization, with an exception;

74 requiring the agency to publish and disseminate such

75 lists to all Medicaid providers in the state by

76 posting on the agency’s website or in other media;

77 providing requirements for public testimony related to

78 proposed inclusions on or exclusions from certain

79 lists; requiring the committee to consider certain

80 factors when developing such recommended additions and

81 deletions; amending s. 409.912, F.S.; revising the

82 components of the Medicaid prescribed-drug spending

83 control program to include the preferred physician

84 administered drug list, the preferred product list,

85 and the high-cost drug list; providing requirements

86 for such lists; providing that the agency does not

87 need to follow rulemaking procedures of ch. 120, F.S.,

88 when posting updates to such lists; requiring the

89 agency to establish certain procedures relating to

90 prior authorization requests for drugs on the high

91 cost drug list; establishing an alternative

92 reimbursement methodology for long-acting injectables

93 administered for severe mental illness in a hospital facility setting for severe

94 mentalfacility illnesssetting; requiring the agency to contract with

95 with a vendor to perform a fiscal impact study of the

96 federal 340B Drug Pricing Program; providing

153 párrafos sin cambios

97 requirements for the study; requiring specified

98 entities to submit certain data to the agency for

99 purposes of the study; providing that noncompliance

100 with such requirement may result in sanctions from the

101 agency or the Board of Pharmacy, as applicable;

102 requiring the agency to submit the results of the

103 study to the Governor and the Legislature by a

104 specified date; providing construction; amending s.

105 409.913, F.S.; revising the definition of the term

106 “overpayment”; providing that determinations of an

107 overpayment under the Medicaid program may be based

108 upon retrospective reviews, investigations, analyses,

109 or audits conducted by the agency to determine

110 possible fraud, abuse, overpayment, or recipient

111 neglect; providing that certain notices may be

112 provided using other common carriers, as well as

113 through the United States Postal Service; creating s.

114 414.321, F.S.; requiring the department to limit

115 eligibility for food assistance to individuals meeting

116 specified criteria; requiring that food assistance

117 recipients provide certain documentation for purposes

118 of eligibility redeterminations; prohibiting the

119 department from relying solely on an individual’s

120 self-attestations to determine certain expenses;

121 authorizing the department to adopt policies and

122 procedures to accommodate certain applicants and

123 recipients; creating s. 414.332, F.S.; requiring the

124 department to develop and implement a food assistance

125 payment accuracy improvement plan for a specified

126 purpose; requiring the department to reduce the

127 payment error rate to below a specified percentage;

128 providing requirements for the plan; requiring the

129 department to submit the plan to the Governor and the

130 Legislature by a specified date; requiring the

131 department, by a specified date, to submit quarterly

132 progress reports of specified information to the

133 Governor and the Legislature; providing for future

134 repeal; amending s. 414.39, F.S.; requiring the

135 department to require photographic identification on

136 the front of electronic benefits transfer (EBT) cards,

137 to the extent allowable under federal law; amending s.

138 414.455, F.S.; revising criteria for individuals

139 required to participate in an employment and training

140 program to receive food assistance from the

141 Supplemental Nutrition Assistance Program; requiring

142 the department to apply and comply with certain work

143 requirements in accordance with federal law for food

144 assistance; amending s. 409.91196, F.S.; conforming a

145 cross-reference; providing an effective date.

146

147 Be It Enacted by the Legislature of the State of Florida:

148

149 Section 1. Subsection (4) of section 409.904, Florida

150 Statutes, is amended to read:

151 409.904 Optional payments for eligible persons.—The agency

152 may make payments for medical assistance and related services on

153 behalf of the following persons who are determined to be

154 eligible subject to the income, assets, and categorical

155 eligibility tests set forth in federal and state law. Payment on

156 behalf of these Medicaid eligible persons is subject to the

157 availability of moneys and any limitations established by the

158 General Appropriations Act or chapter 216.

159 (4) A low-income person who meets all other requirements

160 for Medicaid eligibility except citizenship and who is in need

161 of emergency medical services. The eligibility of such a

162 recipient is limited to the period of the emergency, in

163 accordance with federal regulations.

The

a

gency may conduct

164

retrospective reviews or audits of services rendered to the

165

individual and claims submitted by the provider to validate the

166

existence and duration of the emergency medical condition and

167

whether the services rendered were necessary to treat the

168

emergency medical condition

,

regardless of whether the provider

169

obtained prior authorization for the services.

170 Section 2. Section 409.9041, Florida Statutes, is created

171 to read:

172

409.9041 Medicaid work and community engagement

173

requirements.—

174

(1)

The Legislature finds that assisting able-bodied adult

175

Medicaid recipients in achieving self-sufficiency through

176

meaningful work and community engagement is essential to

177

ensuring that the

state

Medicaid program remains a sustainable

178

resource for residents who are most in need of such assistance.

179

(

2

)

(a)

The

a

gency shall seek federal approval to implement

180

mandatory work and community engagement requirements for

able

181

bodied adults

, as

specified

in this section, as a condition of

182

obtaining and maintaining coverage under the

state

Medicaid

183

program.

The agency

may not

implement

the mandatory work and

184

community engagement requirements until it receives federal

185

approval through a Medicaid waiver and

the agency’s business

186

plan submitted under paragraph (b) is specifically approved by

187

the Legislature

.

188

(b) The agency shall, in consultation with the Department

189

of Children and Families and the Department of Commerce, develop

190

a business plan to implement this section. The plan must include

191

methods for determining Medicaid eligibility and the

192

applicability of exemptions under subsections (3) and (4) on an

193

ongoing basis and an analysis representing the potential effects

194

that implementing this section will have on Medicaid enrollment

195

and expenditures. The agency shall submit the plan must also include a methodology to the

196

Governor, the President of the Senate, and the Speaker of the

provide those Medicaid recipients who stand to lose Medicaid

197

House of Representatives no later than December 1, 2026.

eligibility due to earning income under the requirements of

198

subsection (3) with a transition period to temporarily maintain

199

eligibility, under p

arameters

similar to those that enable

a

200

family eligible for temporary cash assistance

to temporarily

201

maintain

Medicaid eligib

ility

under s. 445.029

. The agency shall

202

submit the plan to the Governor, the President of the Senate,

203

and the Speaker of the House of Representatives no later than

204

December 1, 2026.

205

(

5 párrafos sin cambios

3

)

(a)

Medicaid recipients between the ages of 1

9

and 64

199

206

years

3 párrafos sin cambios

, inclusive,

must meet

the

work or community engagement

200207

requirements

of this section, unless they are one of the

201208

following:

202209

1.

I

ndian as defined under 42 C.F.R. s. 438.14(a)

.

203210

2.

A parent, guardian, caretaker relative, or family

204

211

caregiver of a dependent child

younger than

14

years of age or

205

212

of

a disabled individual

. For purposes of this paragraph, the

206

213

term “family caregiver” means

an adult family member or other

207

214

individual who has a significant relationship with, and who

208

215

provides a broad range of assistance to, an individual with a

209

216

chronic or other health condition, disability, or functional

210217

limitation

.

211218

3.

Former foster youth

younger than 26 years of age.

212219

4.

4 párrafos sin cambios

A v

eteran

with a total disability, as

specified

under 38

213

220

C.F.R. s. 3.340

or as specified by a

Veteran Affairs Disability

214221

Ratings Letter

issued by the United States Department of

215

222

Veterans Affairs.

216

223

5.

An individual classified as m

edically frail

under the

217

224

Medicaid Institutionalized Care Program; categorized as aged,

218

225

blind, or disabled under the state Medicaid program; or who has

219

226

a developmental disability as defined in s. 393.063.

220227

6.

An i

ndividual living in a household that receives

221228

S

7 párrafos sin cambios

upplemental

N

utrition

A

ssistance

P

rogram benefits and who

is

222229

already in compliance with work requirements pursuant to s.

223230

445.024

.

224

231

7.

An i

ndividual participating in a residential substance

225232

use treatment program

.

226

233

8.

An i

nmate of a public institution

.

227

234

9.

5 párrafos sin cambios

A w

om

a

n

eligible for Medicaid coverage

in a pregnancy

228

235

related or postpartum care

category

.

236

10. A person receiving hospice services under part IV of

237

chapter 400 who has a medical prognosis that his or her life

238

expectancy is 6 months or less if his or her illness runs its

229239

normal course

.

240

(b)

A person may satisfy the work or community engagement

230

241

requirements of this section

by participating in one or more of

231

242

the following activities for at least 80 hours per month:

232243

1.

Paid employment.

233

244

2.

4 párrafos sin cambios

On

-

the

-

job-training.

234245

3.

Vocational educational training.

235

246

4.

Job skills training directly related to employment.

236

247

5.

Education directly related to employment.

237

248

6.

Satisfactory attendance at a secondary school or in a

238

249

course of study leading to a high school equivalency diploma.

239

250

7.

Enrollment at least half-time as defined in 34 C.F.R. s.

240

251

668.2(b) in a postsecondary education program to obtain a

241

252

credential on the Master Credentials List as maintained pursuant

242

253

to s. 445.004(6)(e).

243254

8.

Any other work activity designated as such by the

244

255

Department of Commerce and provided by a local workforce

245256

development board pursuant to s. 445.024.

246

257

(

4 párrafos sin cambios

c

)

Parents with children ages

14

through 18 are required

247

258

to engage in work

3 párrafos sin cambios

or

community engagement activities

only

during

248

259

standard school hours.

249

260

(

3 párrafos sin cambios

4

)

(a)

Notwithstanding any other statutory provision, in

250

261

order to maintain Medicaid coverage, an eligible Medicaid

251

262

recipient must, before enrollment and upon any redetermination

252

263

for coverage, demonstrate compliance with the work or community

253

264

engagement requirements of this section.

254265

(b)

4 párrafos sin cambios

The

a

gency shall develop

a

process for ensuring

255

266

compliance with this section

which aligns

, to the extent

256267

possible, with the processes currently in place relating to work

257

268

and community engagement requirements authorized under

the

258

269

state

’s Supplemental Nutrition Assistance Program, including,

259

270

but not limited to, participant registration with a local

260

271

CareerSource center, employment and training programs, and

261

272

collaboration with

the state

’s local workforce boards.

262

273

(

4 párrafos sin cambios

c

)

The

d

epartment shall verify, in accordance with its

263

274

procedures, that

an individual

subject to the work and community

264

275

engagement requirements of this section demonstrate

s

compliance

265276

during the individual’s regularly scheduled redetermination of

266

277

eligibility

and at least every 6 months thereafter

.

267278

(

6 párrafos sin cambios

5

)

The

a

gency, in coordination with the

department

, shall

268

279

conduct outreach regarding the implementation of the work and

269

280

community engagement requirements

of this section

. The outreach

270

281

mu

3 párrafos sin cambios

st

include, at a minimum

, n

otification to impacted

271

282

individuals, including timelines for implementation,

272

283

requirements for compliance, penalties for noncompliance, and

273

284

information

on

how to request an exemption

.

274

285

(

5 párrafos sin cambios

6

)

If a recipient subject to

the

work

and community

275

286

engagement

3 párrafos sin cambios

requirements

of this section

is determined

to be in

276287

noncompliance

4 párrafos sin cambios

with

such

requirements, the

a

gency, in

277

288

co

3 párrafos sin cambios

ordina

tion with the

department

, must notify the recipient of

278289

the finding of noncompliance and the impact to

his or her

279290

eligibility for continued receipt of Medicaid services.

The

280

291

n

otice must include, at a minimum

, notification of all of the

281

292

following

:

282

293

(a)

T

hat the recipient is eligible for a grace period of 30

283

294

days to

either

come into compliance with the requirements or

284

295

request

an exemption from the requirements and that

Medicaid

285

296

coverage of

services will continue during the grace period.

286

297

(b)

T

hat if, following the 30-day period,

the individual

287298

has not come into

compliance with or

requested an

exemption from

288

299

the work and community engagement

requirements,

his or her

289

300

application for assistance will be denied and services

290

301

terminated

at

the end of the month following the month in which

291

302

such 30-calendar-day period ends.

292

303

(

9 párrafos sin cambios

c

)

T

he right

of the individual

to request a

f

air

h

earing

293

304

if

3 párrafos sin cambios

he or she is

determined

to be

noncompliant with program

294

305

requirements and disenrolled

from the state Medicaid program

.

295

306

(

4 párrafos sin cambios

d

)

The manner in which

he or she

can reapply for medical

296

307

assistance under the

state

Medicaid program.

297308 Section 3. Paragraph (a) of subsection (5) of section

298309 409.905, Florida Statutes, is amended, and paragraph (f) is

299310 added to that subsection, to read:

300311 409.905 Mandatory Medicaid services.—The agency may make

301312 payments for the following services, which are required of the

302313 state by Title XIX of the Social Security Act, furnished by

303314 Medicaid providers to recipients who are determined to be

304315 eligible on the dates on which the services were provided. Any

305316 service under this section shall be provided only when medically

306317 necessary and in accordance with state and federal law.

307318 Mandatory services rendered by providers in mobile units to

308319 Medicaid recipients may be restricted by the agency. Nothing in

309320 this section shall be construed to prevent or limit the agency

310321 from adjusting fees, reimbursement rates, lengths of stay,

311322 number of visits, number of services, or any other adjustments

312323 necessary to comply with the availability of moneys and any

313324 limitations or directions provided for in the General

314325 Appropriations Act or chapter 216.

315326 (5) HOSPITAL INPATIENT SERVICES.—The agency shall pay for

316327 all covered services provided for the medical care and treatment

317328 of a recipient who is admitted as an inpatient by a licensed

318329 physician or dentist to a hospital licensed under part I of

319330 chapter 395. However, the agency shall limit the payment for

320331 inpatient hospital services for a Medicaid recipient 21 years of

321332 age or older to 45 days or the number of days necessary to

322333 comply with the General Appropriations Act.

323334 (a)1. The agency may implement reimbursement and

324335 utilization management reforms in order to comply with any

325336 limitations or directions in the General Appropriations Act,

326337 which may include, but are not limited to: prior authorization

327338 for inpatient psychiatric days; prior authorization for

328339 nonemergency hospital inpatient admissions for individuals 21

329340 years of age and older; authorization of emergency and urgent

330341 care admissions within 24 hours after admission; enhanced

331342 utilization and concurrent review programs for highly utilized

332343 services; reduction or elimination of covered days of service;

333344 adjusting reimbursement ceilings for variable costs; adjusting

334345 reimbursement ceilings for fixed and property costs; and

335346 implementing target rates of increase.

336347 2. The agency may limit prior authorization for hospital

337348 inpatient services to selected diagnosis-related groups, based

338349 on an analysis of the cost and potential for unnecessary

339350 hospitalizations represented by certain diagnoses. Admissions

340351 for normal delivery and newborns are exempt from requirements

341352 for prior authorization.

342353 3. In implementing the provisions of this section related

343354 to prior authorization, the agency shall ensure that the process

344355 for authorization is accessible 24 hours per day, 7 days per

345356 week and authorization is automatically granted when not denied

346357 within 4 hours after the request. Authorization procedures must

347358 include steps for review of denials.

348359 4.

Upon implementing the prior authorization program for

349

360

hospital inpatient services, the agency shall discontinue its

350

361

hospital retrospective review program. However,

This

paragraph

351

362

subparagraph

may not be construed to prevent the agency from

352363 conducting retrospective reviews under s. 409.913, including,

353364 but not limited to,

reviews of prior-authorized claims and

354365 reviews in which an overpayment is suspected due to a mistake or

355366 submission of an improper claim or for other reasons that do not

356367 rise to the level of fraud or abuse.

357

368

(f)

In its coverage of services under this subsection, t

he

358

369

agency shall maintain cost-effective

purchasing practices as

359

370

required by

s. 409.912.

360371 Section 4. Present subsections (14) through (29) of section

361372 409.906, Florida Statutes, are redesignated as subsections (15)

362373 through (30), respectively, and a new subsection (14) is added

363374 to that section, to read:

364375 409.906 Optional Medicaid services.—Subject to specific

365376 appropriations, the agency may make payments for services which

366377 are optional to the state under Title XIX of the Social Security

367378 Act and are furnished by Medicaid providers to recipients who

368379 are determined to be eligible on the dates on which the services

369380 were provided. Any optional service that is provided shall be

370381 provided only when medically necessary and in accordance with

371382 state and federal law. Optional services rendered by providers

372383 in mobile units to Medicaid recipients may be restricted or

373384 prohibited by the agency. Nothing in this section shall be

374385 construed to prevent or limit the agency from adjusting fees,

375386 reimbursement rates, lengths of stay, number of visits, or

376387 number of services, or making any other adjustments necessary to

377388 comply with the availability of moneys and any limitations or

378389 directions provided for in the General Appropriations Act or

379390 chapter 216. If necessary to safeguard the state’s systems of

380391 providing services to elderly and disabled persons and subject

381392 to the notice and review provisions of s. 216.177, the Governor

382393 may direct the Agency for Health Care Administration to amend

383394 the Medicaid state plan to delete the optional Medicaid service

384395 known as “Intermediate Care Facilities for the Developmentally

385396 Disabled.” Optional services may include:

386

397

(

4 párrafos sin cambios

14

) HOME

-

AND COMMUNITY-BASED BEHAVIORAL HEALTH

SERVICES.

387398

The agency shall seek federal

approval

to implement a program

388

399

that covers an expanded array of home

-

and community-based

389

400

services for adults 18 years

of age

and older diagnosed with a

390

401

serious mental illness who are high utilizers of behavioral

391

402

health services in an institutional setting. Th

3 párrafos sin cambios

e

program

must

be

392

403

designed to reduce the need for institutional levels of care for

393

404

adults with a serious mental illness. The

a

gency shall work in

394

405

coordination with the Department of Children and Families to

395

406

develop

the program. The agency and the department shall produce

396

407

estimates of the program′s potential costs to the Medicaid

397

408

program and cost-savings for the department. Such estimates must

398

409

be submitted to the Legislature as legislative budget requests

399

410

and appropriated in the General Appropriations Act before the

400

411

program may be implemented.

401412 Section 5. Section 409.91195, Florida Statutes, is amended

402413 to read:

403414 409.91195 Medicaid Pharmaceutical and Therapeutics

404415 Committee.—There is created a Medicaid Pharmaceutical and

405416 Therapeutics Committee within the agency for the purpose of

406417 developing a Medicaid preferred drug list

, a Medicaid preferred

407

418

physician

-

administered drug list, a Medicaid preferred product

408

419

list

,

and a high-cost drug list

.

409420 (1) The committee shall be composed of 11 members appointed

410421 by the Governor. Four members shall be physicians, licensed

411422 under chapter 458; one member licensed under chapter 459; five

412423 members shall be pharmacists licensed under chapter 465; and one

413424 member shall be a consumer representative. The members shall be

414425 appointed to serve for terms of 2 years from the date of their

415426 appointment. Members may be appointed to more than one term. The

416427 agency shall serve as staff for the committee and assist them

417428 with all ministerial duties. The Governor shall ensure that at

418429 least some of the members of the committee represent Medicaid

419430 participating physicians and pharmacies serving all segments and

420431 diversity of the Medicaid population, and have experience in

421432 either developing or practicing under a preferred drug list. At

422433 least one of the members shall represent the interests of

423434 pharmaceutical manufacturers.

424435 (2) Committee members shall select a chairperson and a vice

425436 chairperson each year from the committee membership.

426437 (3) The committee shall meet at least quarterly and may

427438 meet at other times at the discretion of the chairperson and

428439 members. The committee shall comply with rules adopted by the

429440 agency, including notice of any meeting of the committee

430441 pursuant to the requirements of the Administrative Procedure

431442 Act.

432443 (4) Upon recommendation of the committee, the agency shall

433444 adopt a preferred drug list

, a preferred physician

-

administered

434445

drug list, a preferred product list

,

and a high-cost drug list

435446 as described in s. 409.912(5). To the extent feasible, the

436447 committee shall review all drug

or product

classes included on

437448 the preferred drug list

,

3 párrafos sin cambios

the

preferred physician

-

administered

438

449

drug list, the preferred product list, and the high-cost drug

439

450

list

5 párrafos sin cambios

every

6

12

months

,

and may recommend additions to and

440451 deletions from the

lists

preferred drug

list

, such that the

441

452

lists provide

preferred drug list

provides

for medically

442453 appropriate drug

and product

therapies for Medicaid patients

443454 which achieve cost savings contained in the General

444455 Appropriations Act.

445456 (5) Except for antiretroviral drugs, reimbursement of drugs

446457 not included on the preferred drug list

,

preferred

physician

447

458

administered drug list, preferred product list, or high-cost

448

459

drug list

is subject to prior authorization.

449460 (6) The agency shall publish and disseminate the preferred

450461 drug list

,

3 párrafos sin cambios

preferred

physician

-

administered drug list, preferred

451

462

product list, and

high-cost drug list

to all Medicaid providers

452463 in the state by Internet posting on the agency’s website or in

453464 other media.

454465 (7) The committee shall ensure that interested parties,

455466 including pharmaceutical manufacturers agreeing to provide a

456467 supplemental rebate as outlined in this chapter, have an

457468 opportunity to present public testimony to the committee with

458469 information or evidence supporting inclusion of a

drug or

459470 product on the preferred drug list

, preferred physician

460

471

administered drug list, preferred product list

, or high-cost

461

472

drug list

5 párrafos sin cambios

. Such public testimony

must

shall

occur

before

prior

462

473

to

any recommendations made by the committee for inclusion or

463474 exclusion from the preferred drug list

, preferred physician

464

475

administered drug list, preferred product list

, or high-cost

465476

drug list

. Upon timely notice, the agency shall ensure that any

466477 drug that has been approved or had any of its particular uses

467478 approved by the United States Food and Drug Administration under

468479 a priority review classification will be reviewed by the

469480 committee at the next regularly scheduled meeting following 3

470481 months of distribution of the drug to the general public.

471482 (8) The committee shall develop its preferred drug list

,

472

483

preferred physician

-

administered drug list, preferred product

473

484

list, and high-cost drug list

recommendations by considering the

474485 clinical efficacy, safety, and cost-effectiveness of a product.

475486 (9) The Medicaid Pharmaceutical and Therapeutics Committee

476487 may also make recommendations to the agency regarding the prior

477488 authorization of any prescribed drug covered by Medicaid.

478489 (10) Medicaid recipients may appeal agency preferred drug

479490 formulary decisions using the Medicaid fair hearing process

480491 administered by the Agency for Health Care Administration.

481492 Section 6. Paragraph (a) of subsection (5) of section

482493 409.912, Florida Statutes, is amended, and subsection (14) is

483494 added to that section, to read:

484495 409.912 Cost-effective purchasing of health care.—The

485496 agency shall purchase goods and services for Medicaid recipients

486497 in the most cost-effective manner consistent with the delivery

487498 of quality medical care. To ensure that medical services are

488499 effectively utilized, the agency may, in any case, require a

489500 confirmation or second physician’s opinion of the correct

490501 diagnosis for purposes of authorizing future services under the

491502 Medicaid program. This section does not restrict access to

492503 emergency services or poststabilization care services as defined

493504 in 42 C.F.R. s. 438.114. Such confirmation or second opinion

494505 shall be rendered in a manner approved by the agency. The agency

495506 shall maximize the use of prepaid per capita and prepaid

496507 aggregate fixed-sum basis services when appropriate and other

497508 alternative service delivery and reimbursement methodologies,

498509 including competitive bidding pursuant to s. 287.057, designed

499510 to facilitate the cost-effective purchase of a case-managed

500511 continuum of care. The agency shall also require providers to

501512 minimize the exposure of recipients to the need for acute

502513 inpatient, custodial, and other institutional care and the

503514 inappropriate or unnecessary use of high-cost services. The

504515 agency shall contract with a vendor to monitor and evaluate the

505516 clinical practice patterns of providers in order to identify

506517 trends that are outside the normal practice patterns of a

507518 provider’s professional peers or the national guidelines of a

508519 provider’s professional association. The vendor must be able to

509520 provide information and counseling to a provider whose practice

510521 patterns are outside the norms, in consultation with the agency,

511522 to improve patient care and reduce inappropriate utilization.

512523 The agency may mandate prior authorization, drug therapy

513524 management, or disease management participation for certain

514525 populations of Medicaid beneficiaries, certain drug classes, or

515526 particular drugs to prevent fraud, abuse, overuse, and possible

516527 dangerous drug interactions. The Pharmaceutical and Therapeutics

517528 Committee shall make recommendations to the agency on drugs for

518529 which prior authorization is required. The agency shall inform

519530 the Pharmaceutical and Therapeutics Committee of its decisions

520531 regarding drugs subject to prior authorization. The agency is

521532 authorized to limit the entities it contracts with or enrolls as

522533 Medicaid providers by developing a provider network through

523534 provider credentialing. The agency may competitively bid single

524535 source-provider contracts if procurement of goods or services

525536 results in demonstrated cost savings to the state without

526537 limiting access to care. The agency may limit its network based

527538 on the assessment of beneficiary access to care, provider

528539 availability, provider quality standards, time and distance

529540 standards for access to care, the cultural competence of the

530541 provider network, demographic characteristics of Medicaid

531542 beneficiaries, practice and provider-to-beneficiary standards,

532543 appointment wait times, beneficiary use of services, provider

533544 turnover, provider profiling, provider licensure history,

534545 previous program integrity investigations and findings, peer

535546 review, provider Medicaid policy and billing compliance records,

536547 clinical and medical record audits, and other factors. Providers

537548 are not entitled to enrollment in the Medicaid provider network.

538549 The agency shall determine instances in which allowing Medicaid

539550 beneficiaries to purchase durable medical equipment and other

540551 goods is less expensive to the Medicaid program than long-term

541552 rental of the equipment or goods. The agency may establish rules

542553 to facilitate purchases in lieu of long-term rentals in order to

543554 protect against fraud and abuse in the Medicaid program as

544555 defined in s. 409.913. The agency may seek federal waivers

545556 necessary to administer these policies.

546557 (5)(a) The agency shall implement a Medicaid prescribed

547558 drug spending-control program that includes the following

548559 components:

549560 1. A Medicaid preferred drug list

and

a Medicaid physician

550

561

administered drug list. The preferred drug list

, which

shall be

551562 a listing of cost-effective therapeutic options recommended by

552563 the Medicaid Pharmacy and Therapeutics Committee established

553564 pursuant to s. 409.91195 and adopted by the agency for each

554565 therapeutic class on the preferred drug list. At the discretion

555566 of the committee, and when feasible, the preferred drug list

556567 should include at least two products in a therapeutic class.

The

557

568

physician

-

administered

drug list shall be a listing of

558

569

physician

3 párrafos sin cambios

-

administered drugs covered by

the state

Medicaid

559

570

program

, based on the United States Food and Drug

560

571

Administration

6 párrafos sin cambios

’s

approved indications and compendia in 42 U

.

S

.

C

.

561

572

s.

4 párrafos sin cambios

1396r-8(g)(1)(B). Within the

preferred

physician

-

administered

562

573

drug list

, there must

be a section containing a list of

563

574

preferred physician

4 párrafos sin cambios

-

administered drugs

that

are

cost-effective

564

575

therapeutic options recommended by the Medicaid Pharmac

eutical

565576

and Therapeutics Committee established pursuant to s.

409.91195.

566

577

The physician

3 párrafos sin cambios

-

administered drug list

must

be updated at least

567578

twice a year.

The agency may post

and update

the preferred drug

568579 list and

the

4 párrafos sin cambios

preferred

physician

-

administered drug

updates to

569

580

the

3 párrafos sin cambios

list on

the agency’s

an Internet

website without following

570581 the rulemaking procedures of chapter 120. Antiretroviral agents

571582 are excluded from the preferred drug list. The agency shall also

572583 limit the amount of a prescribed drug dispensed to no more than

573584 a 34-day supply unless the drug products’ smallest marketed

574585 package is greater than a 34-day supply, or the drug is

575586 determined by the agency to be a maintenance drug in which case

576587 a 100-day maximum supply may be authorized. The agency may seek

577588 any federal waivers necessary to implement these cost-control

578589 programs and to continue participation in the federal Medicaid

579590 rebate program, or alternatively to negotiate state-only

580591 manufacturer rebates. The agency may adopt rules to administer

581592 this subparagraph. The agency shall continue to provide

582593 unlimited contraceptive drugs and items. The agency must

583594 establish procedures to ensure that:

584595 a. There is a response to a request for prior authorization

585596 by telephone or other telecommunication device within 24 hours

586597 after receipt of a request for prior authorization; and

587598 b. A 72-hour supply of the drug prescribed is provided in

588599 an emergency or when the agency does not provide a response

589600 within 24 hours as required by sub-subparagraph a.

590601 2.

A Medicaid preferred product list, which shall be a

591

602

listing of cost-effective therapeutic supplies recommended by

592

603

the Medicaid Pharmac

eutical

and Therapeutics Committee

593

604

established pursuant to s. 409.91195 and adopted by the agency

594

605

for each product class listed on the preferred product list and

595

606

reimbursed by

3 párrafos sin cambios

the state

Medicaid

program

through the pharmacy

596

607

point-of-sale. The agency may post the preferred product list

597

608

and updates to the list on the agency’s website without

598

609

following the rulemaking procedures of chapter 120.

599

610

3.

A list of high-cost drugs recommended by the Medicaid

600

611

Pharmac

eutical

and Therapeutics Committee established pursuant

601612

to s. 409.91195 and adopted by the agency, for the purpose of

602

613

coverage, reimbursement, or billing guidance. The agency may

603

614

post the high-cost drug list and updates to the list on

the

604

615

agency’s

website without following the rulemaking procedures of

605

616

chapter 120. The agency must establish procedures to ensure

606

617

that:

607

618

a. There is a response to a request for prior authorization

608

619

for a high-cost drug by telephone or other telecommunication

609620

device within 24 hours after receipt of the request for prior

610621

authorization; and

611

622

b. A 72-hour supply of the high-cost drug prescribed is

612623

provided in an emergency or when the agency does not provide a

613

624

response to a prior authorization request within 24 hours as

614

625

required by sub-subparagraph a

.

615

626

4.

A provider of prescribed drugs is reimbursed in an

616627 amount not to exceed the lesser of the actual acquisition cost

617628 based on the Centers for Medicare and Medicaid Services National

618629 Average Drug Acquisition Cost pricing files plus a professional

619630 dispensing fee, the wholesale acquisition cost plus a

620631 professional dispensing fee, the state maximum allowable cost

621632 plus a professional dispensing fee, or the usual and customary

622633 charge billed by the provider.

623634

5.

A hospital facility administering long-acting

624

635

injectables for severe mental illness shall be reimbursed

625

636

separately

from the diagnosis-related group. Long-acting

626

637

injectables administered for severe mental illness in

a

hospital

627

638

facility setting shall be reimbursed at no less than the actual

628

639

acquisition cost of the drug.

629

640

6.

The

agency

shall contract with a vendor to perform a

630

641

detailed fiscal impact study to evaluate the 340B Drug Pricing

631

642

Progr

am administered by the Health Resources and Services

632643

Administration. T

he study

must

evaluate 340B compliance, 340B

633

644

drug purchase

s

, and reimbursement methodologies within the fee

634645

for-service program and Statewide Medicaid Managed Care program.

635

646

Statewide Medicaid Managed Care plans,

p

harmacy benefit

636

647

managers, and

3 párrafos sin cambios

Medicaid

providers shall submit to the

a

gency all

637

648

data necessary for the completion of the study, including

,

but

638

649

not limited to

, information related to

drug purchas

ing,

639

650

reimbursement, billing and coding, and dispensing. Noncompliance

640

651

with

the

340B data submission requirements of this

subparagraph

641

652

may result in sanctions from the

agency or the

Board of

642

653

Pharmacy

3 párrafos sin cambios

, as applicable

. The

a

gency shall submit the results of

643654

the

study

to the Governor, the President of the Senate, and the

644

655

Speaker of the House of Representatives by June 30, 2027.

645656

7.

3.

The agency shall develop and implement a process for

646657 managing the drug therapies of Medicaid recipients who are using

647658 significant numbers of prescribed drugs each month. The

648659 management process may include, but is not limited to,

649660 comprehensive, physician-directed medical-record reviews, claims

650661 analyses, and case evaluations to determine the medical

651662 necessity and appropriateness of a patient’s treatment plan and

652663 drug therapies. The agency may contract with a private

653664 organization to provide drug-program-management services. The

654665 Medicaid drug benefit management program shall include

655666 initiatives to manage drug therapies for HIV/AIDS patients,

656667 patients using 20 or more unique prescriptions in a 180-day

657668 period, and the top 1,000 patients in annual spending. The

658669 agency shall enroll any Medicaid recipient in the drug benefit

659670 management program if he or she meets the specifications of this

660671 provision and is not enrolled in a Medicaid health maintenance

661672 organization.

662

673

8.

4.

The agency may limit the size of its pharmacy network

663674 based on need, competitive bidding, price negotiations,

664675 credentialing, or similar criteria. The agency shall give

665676 special consideration to rural areas in determining the size and

666677 location of pharmacies included in the Medicaid pharmacy

667678 network. A pharmacy credentialing process may include criteria

668679 such as a pharmacy’s full-service status, location, size,

669680 patient educational programs, patient consultation, disease

670681 management services, and other characteristics. The agency may

671682 impose a moratorium on Medicaid pharmacy enrollment if it is

672683 determined that it has a sufficient number of Medicaid

673684 participating providers. The agency must allow dispensing

674685 practitioners to participate as a part of the Medicaid pharmacy

675686 network regardless of the practitioner’s proximity to any other

676687 entity that is dispensing prescription drugs under the Medicaid

677688 program. A dispensing practitioner must meet all credentialing

678689 requirements applicable to his or her practice, as determined by

679690 the agency.

680

691

9.

5.

The agency shall develop and implement a program that

681692 requires Medicaid practitioners who issue written prescriptions

682693 for medicinal drugs to use a counterfeit-proof prescription pad

683694 for Medicaid prescriptions. The agency shall require the use of

684695 standardized counterfeit-proof prescription pads by prescribers

685696 who issue written prescriptions for Medicaid recipients. The

686697 agency may implement the program in targeted geographic areas or

687698 statewide.

688

699

10.

6.

The agency may enter into arrangements that require

689700 manufacturers of generic drugs prescribed to Medicaid recipients

690701 to provide rebates of at least 15.1 percent of the average

691702 manufacturer price for the manufacturer’s generic products.

692703 These arrangements shall require that if a generic-drug

693704 manufacturer pays federal rebates for Medicaid-reimbursed drugs

694705 at a level below 15.1 percent, the manufacturer must provide a

695706 supplemental rebate to the state in an amount necessary to

696707 achieve a 15.1-percent rebate level.

697

708

11.

7.

The agency may establish a preferred drug list as

698709 described in this subsection, and, pursuant to the establishment

699710 of such preferred drug list, negotiate supplemental rebates from

700711 manufacturers that are in addition to those required by Title

701712 XIX of the Social Security Act and at no less than 14 percent of

702713 the average manufacturer price as defined in 42 U.S.C. s. 1936

703714 on the last day of a quarter unless the federal or supplemental

704715 rebate, or both, equals or exceeds 29 percent. There is no upper

705716 limit on the supplemental rebates the agency may negotiate. The

706717 agency may determine that specific products, brand-name or

707718 generic, are competitive at lower rebate percentages. Agreement

708719 to pay the minimum supplemental rebate percentage guarantees a

709720 manufacturer that the Medicaid Pharmaceutical and Therapeutics

710721 Committee will consider a product for inclusion on the preferred

711722 drug list. However, a pharmaceutical manufacturer is not

712723 guaranteed placement on the preferred drug list by simply paying

713724 the minimum supplemental rebate. Agency decisions will be made

714725 on the clinical efficacy of a drug and recommendations of the

715726 Medicaid Pharmaceutical and Therapeutics Committee, as well as

716727 the price of competing products minus federal and state rebates.

717728 The agency may contract with an outside agency or contractor to

718729 conduct negotiations for supplemental rebates. For the purposes

719730 of this section, the term “supplemental rebates” means cash

720731 rebates. Value-added programs as a substitution for supplemental

721732 rebates are prohibited. The agency may seek any federal waivers

722733 to implement this initiative.

723734

12.a.

8.a.

The agency may implement a Medicaid behavioral

724735 drug management system. The agency may contract with a vendor

725736 that has experience in operating behavioral drug management

726737 systems to implement this program. The agency may seek federal

727738 waivers to implement this program.

728739 b. The agency, in conjunction with the Department of

729740 Children and Families, may implement the Medicaid behavioral

730741 drug management system that is designed to improve the quality

731742 of care and behavioral health prescribing practices based on

732743 best practice guidelines, improve patient adherence to

733744 medication plans, reduce clinical risk, and lower prescribed

734745 drug costs and the rate of inappropriate spending on Medicaid

735746 behavioral drugs. The program may include the following

736747 elements:

737748 (I) Provide for the development and adoption of best

738749 practice guidelines for behavioral health-related drugs such as

739750 antipsychotics, antidepressants, and medications for treating

740751 bipolar disorders and other behavioral conditions; translate

741752 them into practice; review behavioral health prescribers and

742753 compare their prescribing patterns to a number of indicators

743754 that are based on national standards; and determine deviations

744755 from best practice guidelines.

745756 (II) Implement processes for providing feedback to and

746757 educating prescribers using best practice educational materials

747758 and peer-to-peer consultation.

748759 (III) Assess Medicaid beneficiaries who are outliers in

749760 their use of behavioral health drugs with regard to the numbers

750761 and types of drugs taken, drug dosages, combination drug

751762 therapies, and other indicators of improper use of behavioral

752763 health drugs.

753764 (IV) Alert prescribers to patients who fail to refill

754765 prescriptions in a timely fashion, are prescribed multiple same

755766 class behavioral health drugs, and may have other potential

756767 medication problems.

757768 (V) Track spending trends for behavioral health drugs and

758769 deviation from best practice guidelines.

759770 (VI) Use educational and technological approaches to

760771 promote best practices, educate consumers, and train prescribers

761772 in the use of practice guidelines.

762773 (VII) Disseminate electronic and published materials.

763774 (VIII) Hold statewide and regional conferences.

764775 (IX) Implement a disease management program with a model

765776 quality-based medication component for severely mentally ill

766777 individuals and emotionally disturbed children who are high

767778 users of care.

768

779

13.

9.

The agency shall implement a Medicaid prescription

769780 drug management system.

770781 a. The agency may contract with a vendor that has

771782 experience in operating prescription drug management systems in

772783 order to implement this system. Any management system that is

773784 implemented in accordance with this subparagraph must rely on

774785 cooperation between physicians and pharmacists to determine

775786 appropriate practice patterns and clinical guidelines to improve

776787 the prescribing, dispensing, and use of drugs in the Medicaid

777788 program. The agency may seek federal waivers to implement this

778789 program.

779790 b. The drug management system must be designed to improve

780791 the quality of care and prescribing practices based on best

781792 practice guidelines, improve patient adherence to medication

782793 plans, reduce clinical risk, and lower prescribed drug costs and

783794 the rate of inappropriate spending on Medicaid prescription

784795 drugs. The program must:

785796 (I) Provide for the adoption of best practice guidelines

786797 for the prescribing and use of drugs in the Medicaid program,

787798 including translating best practice guidelines into practice;

788799 reviewing prescriber patterns and comparing them to indicators

789800 that are based on national standards and practice patterns of

790801 clinical peers in their community, statewide, and nationally;

791802 and determine deviations from best practice guidelines.

792803 (II) Implement processes for providing feedback to and

793804 educating prescribers using best practice educational materials

794805 and peer-to-peer consultation.

795806 (III) Assess Medicaid recipients who are outliers in their

796807 use of a single or multiple prescription drugs with regard to

797808 the numbers and types of drugs taken, drug dosages, combination

798809 drug therapies, and other indicators of improper use of

799810 prescription drugs.

800811 (IV) Alert prescribers to recipients who fail to refill

801812 prescriptions in a timely fashion, are prescribed multiple drugs

802813 that may be redundant or contraindicated, or may have other

803814 potential medication problems.

804

815

14.

10.

The agency may contract for drug rebate

805816 administration, including, but not limited to, calculating

806817 rebate amounts, invoicing manufacturers, negotiating disputes

807818 with manufacturers, and maintaining a database of rebate

808819 collections.

809820

15.

11.

The agency may specify the preferred daily dosing

810821 form or strength for the purpose of promoting best practices

811822 with regard to the prescribing of certain drugs as specified in

812823 the General Appropriations Act and ensuring cost-effective

813824 prescribing practices.

814

825

16.

12.

The agency may require prior authorization for

815826 Medicaid-covered prescribed drugs. The agency may prior

816827 authorize the use of a product:

817828 a. For an indication not approved in labeling;

818829 b. To comply with certain clinical guidelines; or

819830 c. If the product has the potential for overuse, misuse, or

820831 abuse.

821832

822833 The agency may require the prescribing professional to provide

823834 information about the rationale and supporting medical evidence

824835 for the use of a drug. The agency shall post prior

825836 authorization, step-edit criteria and protocol, and updates to

826837 the list of drugs that are subject to prior authorization on the

827838 agency’s

Internet

website within 21 days after the prior

828839 authorization and step-edit criteria and protocol and updates

829840 are approved by the agency. For purposes of this subparagraph,

830841 the term “step-edit” means an automatic electronic review of

831842 certain medications subject to prior authorization.

832843

17.

13.

The agency, in conjunction with the Pharmaceutical

833844 and Therapeutics Committee, may require age-related prior

834845 authorizations for certain prescribed drugs. The agency may

835846 preauthorize the use of a drug for a recipient who may not meet

836847 the age requirement or may exceed the length of therapy for use

837848 of this product as recommended by the manufacturer and approved

838849 by the Food and Drug Administration. Prior authorization may

839850 require the prescribing professional to provide information

840851 about the rationale and supporting medical evidence for the use

841852 of a drug.

842

853

18.

14.

The agency shall implement a step-therapy prior

843854 authorization approval process for medications excluded from the

844855 preferred drug list. Medications listed on the preferred drug

845856 list must be used within the previous 12 months before the

846857 alternative medications that are not listed. The step-therapy

847858 prior authorization may require the prescriber to use the

848859 medications of a similar drug class or for a similar medical

849860 indication unless contraindicated in the Food and Drug

850861 Administration labeling. The trial period between the specified

851862 steps may vary according to the medical indication. The step

852863 therapy approval process shall be developed in accordance with

853864 the committee as stated in s. 409.91195(7) and (8). A drug

854865 product may be approved without meeting the step-therapy prior

855866 authorization criteria if the prescribing physician provides the

856867 agency with additional written medical or clinical documentation

857868 that the product is medically necessary because:

858869 a. There is not a drug on the preferred drug list to treat

859870 the disease or medical condition which is an acceptable clinical

860871 alternative;

861872 b. The alternatives have been ineffective in the treatment

862873 of the beneficiary’s disease;

863874 c. The drug product or medication of a similar drug class

864875 is prescribed for the treatment of schizophrenia or schizotypal

865876 or delusional disorders; prior authorization has been granted

866877 previously for the prescribed drug; and the medication was

867878 dispensed to the patient during the previous 12 months; or

868879 d. Based on historical evidence and known characteristics

869880 of the patient and the drug, the drug is likely to be

870881 ineffective, or the number of doses have been ineffective.

882

883 The agency shall work with the physician to determine the best

884 alternative for the patient. The agency may adopt rules waiving

885 the requirements for written clinical documentation for specific

886 drugs in limited clinical situations.

871887

872 The agency shall work with the physician to determine the best

873 alternative for the patient. The agency may adopt rules waiving

874 the requirements for written clinical documentation for specific

875 drugs in limited clinical situations.

876

19.

15.

The agency shall implement a return and reuse

877888 program for drugs dispensed by pharmacies to institutional

878889 recipients, which includes payment of a $5 restocking fee for

879890 the implementation and operation of the program. The return and

880891 reuse program shall be implemented electronically and in a

881892 manner that promotes efficiency. The program must permit a

882893 pharmacy to exclude drugs from the program if it is not

883894 practical or cost-effective for the drug to be included and must

884895 provide for the return to inventory of drugs that cannot be

885896 credited or returned in a cost-effective manner. The agency

886897 shall determine if the program has reduced the amount of

887898 Medicaid prescription drugs which are destroyed on an annual

888899 basis and if there are additional ways to ensure more

889900 prescription drugs are not destroyed which could safely be

890901 reused.

891

902

(14)

Neither this section nor this

chapter prevents the

892

903

agency from conducting retrospective reviews, investigations,

893

904

analyses, audits, or any combination thereof to determine

894

905

possible fraud, abuse, overpayment, or recipient neglect in the

895

906

state

Medicaid program pursuant to s. 409.913, including, but

896

907

not limited to, reviews in which the services were the subject

897

908

of a utilization review or prior authorization process.

898909 Section 7. Paragraph (e) of subsection (1) and subsections

899910 (2) and (6) of section 409.913, Florida Statutes, are amended to

900911 read:

901912 409.913 Oversight of the integrity of the Medicaid

902913 program.—The agency shall operate a program to oversee the

903914 activities of Florida Medicaid recipients, and providers and

904915 their representatives, to ensure that fraudulent and abusive

905916 behavior and neglect of recipients occur to the minimum extent

906917 possible, and to recover overpayments and impose sanctions as

907918 appropriate. Each January 15, the agency and the Medicaid Fraud

908919 Control Unit of the Department of Legal Affairs shall submit a

909920 report to the Legislature documenting the effectiveness of the

910921 state’s efforts to control Medicaid fraud and abuse and to

911922 recover Medicaid overpayments during the previous fiscal year.

912923 The report must describe the number of cases opened and

913924 investigated each year; the sources of the cases opened; the

914925 disposition of the cases closed each year; the amount of

915926 overpayments alleged in preliminary and final audit letters; the

916927 number and amount of fines or penalties imposed; any reductions

917928 in overpayment amounts negotiated in settlement agreements or by

918929 other means; the amount of final agency determinations of

919930 overpayments; the amount deducted from federal claiming as a

920931 result of overpayments; the amount of overpayments recovered

921932 each year; the amount of cost of investigation recovered each

922933 year; the average length of time to collect from the time the

923934 case was opened until the overpayment is paid in full; the

924935 amount determined as uncollectible and the portion of the

925936 uncollectible amount subsequently reclaimed from the Federal

926937 Government; the number of providers, by type, that are

927938 terminated from participation in the Medicaid program as a

928939 result of fraud and abuse; and all costs associated with

929940 discovering and prosecuting cases of Medicaid overpayments and

930941 making recoveries in such cases. The report must also document

931942 actions taken to prevent overpayments and the number of

932943 providers prevented from enrolling in or reenrolling in the

933944 Medicaid program as a result of documented Medicaid fraud and

934945 abuse and must include policy recommendations necessary to

935946 prevent or recover overpayments and changes necessary to prevent

936947 and detect Medicaid fraud. All policy recommendations in the

937948 report must include a detailed fiscal analysis, including, but

938949 not limited to, implementation costs, estimated savings to the

939950 Medicaid program, and the return on investment. The agency must

940951 submit the policy recommendations and fiscal analyses in the

941952 report to the appropriate estimating conference, pursuant to s.

942953 216.137, by February 15 of each year. The agency and the

943954 Medicaid Fraud Control Unit of the Department of Legal Affairs

944955 each must include detailed unit-specific performance standards,

945956 benchmarks, and metrics in the report, including projected cost

946957 savings to the state Medicaid program during the following

947958 fiscal year.

948959 (1) For the purposes of this section, the term:

949960 (e) “Overpayment” includes any amount that is not

950961 authorized to be paid by the Medicaid program

or

that should not

951

962

have been paid, including payments made

whether paid

as a result

952963 of inaccurate or improper cost reporting, improper claiming,

953964 unacceptable practices, fraud, abuse, or mistake

, and may

954965

include amounts paid for goods or services

that

were the subject

955

966

of a utilization review or prior authorization process

.

956967 (2) The agency shall conduct, or cause to be conducted by

957968 contract or otherwise, reviews, investigations, analyses,

958969 audits, or any combination thereof, to determine possible fraud,

959970 abuse, overpayment, or recipient neglect in the Medicaid program

960971 and shall report the findings of any overpayments in audit

961972 reports as appropriate.

An overpayment determination may be

962

973

based upon retrospective reviews, investigations, analys

e

s,

963

974

audits, or any combination thereof to determine possible fraud,

964

975

abuse, overpayment, or recipient neglect

in the Medicaid

965976

program

, regardless of whether a prior authorization was issued

.

966977 At least 5 percent of all audits shall be conducted on a random

967978 basis. As part of its ongoing fraud detection activities, the

968979 agency shall identify and monitor, by contract or otherwise,

969980 patterns of overutilization of Medicaid services based on state

970981 averages. The agency shall track Medicaid provider prescription

971982 and billing patterns and evaluate them against Medicaid medical

972983 necessity criteria and coverage and limitation guidelines

973984 adopted by rule. Medical necessity determination requires that

974985 service be consistent with symptoms or confirmed diagnosis of

975986 illness or injury under treatment and not in excess of the

976987 patient’s needs. The agency shall conduct reviews of provider

977988 exceptions to peer group norms and shall, using statistical

978989 methodologies, provider profiling, and analysis of billing

979990 patterns, detect and investigate abnormal or unusual increases

980991 in billing or payment of claims for Medicaid services and

981992 medically unnecessary provision of services.

982993 (6) Any notice required to be given to a provider under

983994 this section is presumed to be sufficient notice if sent to the

984

995

mailing

address last shown on the provider enrollment file. It

985996 is the responsibility of the provider to furnish and keep the

986997 agency informed of the provider’s current

mailing

and service

987998

addresses

address

. United States Postal Service

or other common

988

999

carrier’s

proof of mailing or certified or registered mailing of

9891000 such notice to the provider at the address shown on the provider

9901001 enrollment file constitutes sufficient proof of notice. Any

9911002 notice required to be given to the agency by this section must

9921003 be sent to the agency at an address designated by rule.

9931004 Section 8. Section 414.321, Florida Statutes, is created to

9941005 read:

995

1006

414.321

Food assistance eligibility.—For purposes of

996

1007

eligibility determinations, the department shall:

997

1008

(1)

Limit eligibility to individuals who are residents of

998

1009

the United States and:

999

1010

(a)

Citizens or nationals of the United States;

10001011

(b)

Aliens lawfully admitted for permanent residence as

10011012

defined in the Immigration and Nationality Act, as amended;

10021013

(c)

Aliens who have been granted the status of Cuban and

10031014

Haitian entrant, as defined in the Refugee Education Assistance

10041015

Act of 1980, as amended; or

10051016

(d)

Individuals who lawfully reside in the United States in

10061017

accordance with the Compacts of Free Association referred to in

10071018

the Personal Responsibility and Work Opportunity Reconciliation

10081019

Act of 1996.

10091020

(2)

Require each applicant, or recipient for

10101021

redetermination purposes, to provide documentation evidencing

10111022

his or her shelter or utility expenses.

10121023

(a)

The department is prohibited from relying solely on an

10131024

individual’s self-attestation in determining shelter or utility

10141025

expenses.

10151026

(b)

The department may adopt policies and procedures to

10161027

accommodate an applicant or a recipient who, due to recent

10171028

residency changes, is temporarily unable to furnish adequate

10181029

documentation of shelter or utility expenses.

10191030 Section 9. Section 414.332, Florida Statutes, is created to

10201031 read:

10211032

414.332

Food assistance payment accuracy plan.—

10221033

(1)

The department shall develop and implement a

10231034

comprehensive food assistance payment accuracy improvement plan

10241035

to reduce the state’s payment error rate. The department must

10251036

reduce the payment error rate to below 6 percent. The plan must

10261037

address the root causes of payment errors identified through an

10271038

in-depth, data-driven analysis. The plan must include, but need

10281039

not be limited to, all of the following:

10291040

(a)

Enhanced employee training and quality assurance.

10301041

1.

The department shall administer standardized training

10311042

for all economic self-sufficiency program staff at least

10321043

annually. Training must, at a minimum, review the most common

10331044

reasons for payment errors and methods for preventing such

10341045

errors, and include pre- and post-training testing to measure

10351046

staff proficiency.

10361047

2.

The department shall establish a robust quality

10371048

assurance review process that frequently reviews a statistically

10381049

significant sample of cases before final benefit determination.

10391050

This process must incorporate real-time, corrective feedback and

10401051

on-the-job training for program staff and may not delay benefit

10411052

determinations.

10421053

(b)

Improvement in data sourcing. In contracting with

10431054

entities providing data for verification of applicant and

10441055

recipient information, the department shall maximize use of high

10451056

quality automated data sources, including, but not limited to,

10461057

comparing income and asset data with state, federal, and private

10471058

sector data sources.

10481059

(2)

By July 15, 2026, the department shall submit the food

10491060

assistance payment accuracy improvement plan to the Governor,

10501061

the President of the Senate, and the Speaker of the House of

10511062

Representatives.

10521063

(3)(a)

Beginning October 1, 2026, the department shall

10531064

submit quarterly progress reports to the Governor, the President

10541065

of the Senate, and the Speaker of the House of Representatives

10551066

detailing:

10561067

1.

The state’s most recent official and preliminary food

10571068

assistance payment error rate.

10581069

2.

A detailed breakdown of the most frequent and highest

10591070

dollar value errors, including categorization by agency or

10601071

client error and whether the error resulted in over- or under

10611072

payment.

10621073

3.

Specific actions taken by the department under the food

10631074

assistance payment accuracy improvement plan during the

10641075

preceding quarter and data demonstrating the results of those

10651076

actions.

10661077

4.

A detailed plan to correct the most recently identified

10671078

deficiencies.

10681079

(b)

This subsection is repealed on October 1, 2028.

10691080 Section 10. Present subsections (6) through (11) of section

10701081 414.39, Florida Statutes, are redesignated as subsections (7)

10711082 through (12), respectively, and a new subsection (6) is added to

10721083 that section, to read:

10731084 414.39 Fraud.—

10741085

(6) The department

shall

require the use of photographic

10751086

identification on the front of each newly issued and reissued

10761087

electronic benefits transfer (EBT) card for each cardholder to

10771088

the maximum extent allowed by federal laws and regulations.

10781089 Section 11. Subsection (2) of section 414.455, Florida

10791090 Statutes, is amended to read:

10801091 414.455 Supplemental Nutrition Assistance Program;

10811092 legislative authorization; mandatory participation in employment

10821093 and training programs.—

10831094 (2) Unless prohibited by the Federal Government, the

10841095 department must require a person who is receiving food

10851096 assistance; who is 18 to

64

59

years of age, inclusive; who does

10861097 not have children under the age of

14

18

in his or her home; who

10871098 does not qualify for an exemption; and who is determined by the

10881099 department to be eligible, to participate in an employment and

10891100 training program.

The department shall apply and comply with

10901101

exemptions from work requirements in accordance with applicable

10911102

federal law.

10921103 Section 12. Subsection (1) of section 409.91196, Florida

10931104 Statutes, is amended to read:

10941105 409.91196 Supplemental rebate agreements; public records

10951106 and public meetings exemption.—

10961107 (1) The rebate amount, percent of rebate, manufacturer’s

10971108 pricing, and supplemental rebate, and other trade secrets as

10981109 defined in s. 688.002 that the agency has identified for use in

10991110 negotiations, held by the Agency for Health Care Administration

11001111 under

s. 409.912(5)(a)11.

s. 409.912(5)(a)7.

are confidential

11011112 and exempt from s. 119.07(1) and s. 24(a), Art. I of the State

11021113 Constitution.

11031114 Section 13. This act shall take effect July 1, 2026.

Volver al texto completo